the development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1治疗性抗体的发展中和同源和异源基因型登革热病毒1型.pdf

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 1 1 1 2 2 Bimmi Shrestha , James D. Brien , Soila Sukupolvi-Petty , S. Kyle Austin , Melissa A. Edeling , Taekyung 2 1 2 3 2,4,5 Kim , Katie M. O’Brien , Christopher A. Nelson , Syd Johnson , Daved H. Fremont , Michael S. Diamond1,2,5,6* 1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Pathology Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 MacroGenics, Inc., Rockville, Maryland, United States of America, 4 Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 5 The Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Washington University School of Medicine, St. Louis, Missouri, United States of America, 6 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America Abstract Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous